Emergent BioSolutions (EBS) Current Assets (2010 - 2026)

Emergent BioSolutions' Current Assets history runs 17 years deep, the most recent figure standing at $637.6 million for Q1 2026.

• In Q1 2026, Current Assets fell 9.79% year-over-year to $637.6 million; the TTM figure through Mar 2026 stood at $637.6 million (down 9.79% YoY), while the FY2025 annual figure was $662.5 million, up 10.66% from the prior year.
• Current Assets was $637.6 million for Q1 2026 at Emergent BioSolutions, down from $662.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.2 billion in Q1 2023 to a low of $598.7 million in Q4 2024.
• Historically, Current Assets has averaged $823.7 million across 5 years, with a median of $719.5 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Current Assets plunged 44.13% in 2024, then grew 18.97% in 2025.
• A 5-year view of Current Assets shows it stood at $1.2 billion in 2022, then sank by 43.86% to $679.5 million in 2023, then retreated by 11.89% to $598.7 million in 2024, then advanced by 10.66% to $662.5 million in 2025, then retreated by 3.76% to $637.6 million in 2026.
• The last three Current Assets figures came in at $637.6 million (Q1 2026), $662.5 million (Q4 2025), and $786.9 million (Q3 2025), per Business Quant data.